Search Results - "Owonikoko, Taofeek Kunle"

Efficacy and safety of immune checkpoint blockade in self‐identified Black patients with advanced non–small cell lung cancer by Nazha, Bassel, Goyal, Subir, Chen, Zhengjia, Engelhart, Anne, Carlisle, Jennifer Wilkinson, Beardslee, Tyler J., Gill, Harpaul, Odikadze, Levani, Liu, Yuan, Mishra, Manoj K., Ramalingam, Suresh S., Owonikoko, Taofeek Kunle

“…Background To the authors' knowledge, race‐based differences in efficacy for the treatment of patients with advanced non–small cell lung cancer (NSCLC) have…”
Get full text

Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006 by Gray, Jhanelle Elaine, Owonikoko, Taofeek Kunle, Kato, Terufumi, Cardona Zorrilla, Andres Felipe, Wagman, Joanne, Chen, Xinqun, Zhao, Bin, Schulz, Christian

“…Abstract only TPS9632 Background: First-line treatment with pembrolizumab + pemetrexed/platinum improved clinical outcomes in patients with advanced…”
Get full text

First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70 by Owonikoko, Taofeek Kunle, Hussain, Arif, Stadler, Walter Michael, Smith, David C., Kluger, Harriet, Molina, Ana M., Gulati, Parul, Shah, Aadhar, Ahlers, Christoph Matthias, Cardarelli, Pina M., Cohen, Lewis J.

“…Purpose The study evaluated the safety, tolerability, and pharmacokinetics of BMS-936561, a fully human monoclonal antibody-drug conjugate targeting CD70…”
Get full text

Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869) by Khan, Mohammad Khurram, Nasti, Tahseen, Yushak, Melinda Lynne, Lawson, David H., Switchenko, Jeffrey M., Wallington, David, Kleber, Troy, Kirmani, Khadija, Owonikoko, Taofeek Kunle, Ramalingam, Suresh S., Ahmed, Rafi

“…Abstract only e22002 Background: The safety and efficacy of concurrent radiotherapy (SRS) and single agent (anti-PD-1) checkpoint inhibitor have not been…”
Get full text

Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders by Beckermann, Katy, Bestvina, Christine M., Whisenant, Jennifer G., Borghaei, Hossein, Owonikoko, Taofeek Kunle, Berry, Lynne D, Shyr, Yu, Liang, Chris, Selvaggi, Giovanni, Wakelee, Heather A., Horn, Leora

“…Abstract only e21019 Background: VEGF inhibition is suggested to enhance innate T cell function, activate dendritic cells, block recruitment of regulatory T…”
Get full text

Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC) by Smit, Marie-Anne Damiette, Borghaei, Hossein, Owonikoko, Taofeek Kunle, Hummel, Horst-Dieter, Johnson, Melissa Lynne, Champiat, Stéphane, Salgia, Ravi, Udagawa, Hibiki, Boyer, Michael J., Govindan, Ramaswamy

“…Abstract only TPS8577 Background: SCLC is an aggressive neuroendocrine tumor; response to initial chemotherapy and radiotherapy is often followed by…”
Get full text

Efficacy and safety of immune checkpoint blockade in self-identified Blacks with advanced non-small cell lung cancer (NSCLC) by Nazha, Bassel, Goyal, Subir, Chen, Zhengjia, Engelhart, Anne, Carlisle, Jennifer Wilkinson, Beardslee, Tyler J., Gill, Harpaul, Odikadze, Levani, Liu, Yuan, Mishra, Manoj K., Ramalingam, Suresh S., Owonikoko, Taofeek Kunle

“…We performed a retrospective study of overall survival (OS) and progression free survival (PFS) of non-small cell lung cancer patients treated with single…”
Get full text

YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival by Owonikoko, Taofeek Kunle, Dwivedi, Bhakti, Chen, Zhengjia, Zhang, Chao, Barwick, Benjamin, Gilbert-Ross, Melissa, Ernani, Vinicius, Barwick, Benjamin, Zhang, Guojing, Carlisle, Jennifer W, Khuri, Fadlo Raja, Curran, Walter J, Lonial, Sagar, Ramalingam, Suresh S., Sun, Shi-Yong, Waller, Edmund K., Sica, Gabriel

“…Abstract only 9019 Background: The dominant expression of transcription factors ASCL1, NeuroD1, YAP1 or POU2F3 characteristically defines four small cell lung…”
Get full text

A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007 by Yap, Timothy A, Dhawan, Mallika Sachdev, Hendifar, Andrew Eugene, Maio, Michele, Owonikoko, Taofeek Kunle, Quintela-Fandino, Miguel, Shapira, Roni, Saraf, Sanatan, Qiu, Ping, Jin, Fan, Gozman, Alexander, Levine, Douglas A

“…Abstract only TPS3156 Background: The anti-PD-1 antibody pembrolizumab (pembro) has improved clinical outcomes in multiple previously treated advanced solid…”
Get full text

KRAS G12C mutation associated outcomes among patients with locally advanced non-small cell lung cancer by Qian, David, Behera, Madhusmita, Steuer, Conor Ernst, Pakkala, Suchita, Carlisle, Jennifer W, Owonikoko, Taofeek Kunle, Fischer-Valuck, Benjamin Walker, Kesarwala, Aparna Hemant, Bradley, Jeffrey, Curran, Walter J, Ramalingam, Suresh S., Higgins, Kristin Ann

“…Abstract only e21079 Background: Recent progress in targeted therapy includes the demonstration of promising anti-tumor activity and safety of a KRAS inhibitor…”
Get full text

Impact of TP53 mutations on efficacy of PD-1 targeted immunotherapy in non-small cell lung cancer (NSCLC) by Carlisle, Jennifer Wilkinson, Nho, Nhu Thi, Kim, Chaejin, Chen, Zhengjia, Li, Shiyong, Hill, Charles, Ramalingam, Suresh S., Sica, Gabriel, Owonikoko, Taofeek Kunle

“…Abstract only…”
Get full text

Safety and efficacy of combining pembrolizmumab and dose escalation/fraction de-escalation SRS for melanoma and NSCLC brain metastasis: Preliminary results from arm a of a prospective pilot trial by Khan, Mohammad Khurram, Nasti, Tahseen, Masoumy, Lily, Kamphorst, Alice O., Yushak, Melinda I, Owonikoko, Taofeek Kunle, Kudchadkar, Ragini Reiney, Ramalingam, Suresh S., Lawson, David H., Ahmed, Rafi

“…Abstract only…”
Get full text

Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience by Nazha, Bassel, Chen, Zhengjia, Goyal, Subir, Engelhart, Anne, Carlisle, Jennifer Wilkinson, Beardslee, Tyler, Gill, Harpaul, Odikadze, Levani, Liu, Yuan, Mishra, Manoj K., Behera, Madhusmita, Ramalingam, Suresh S., Owonikoko, Taofeek Kunle

“…Abstract only 9042 Background: Race-based differences in ICI efficacy for advanced NSCLC have not been studied due to under-representation of patients of…”
Get full text

NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer by Ross, Helen J., Hu, Chen, Higgins, Kristin Ann, Jabbour, Salma K., Kozono, David E., Owonikoko, Taofeek Kunle, Movsas, Benjamin, Solberg, Timothy, Xiao, Canhua, Williams, Terence Marques, Welsh, James William, Simko, Jeffry, Wang, Xiaofei F., Mohindra, Nisha Anjali, Hsu, Charles, Stinchcombe, Tom, Bradley, Jeffrey

“…Abstract only TPS9082 Background: Limited stage small cell lung cancer (LS-SCLC) is treated with standard of care platinum/etoposide (EP) and thoracic…”
Get full text

Selpercatinib (LOXO-292) in patients with RET -mutant medullary thyroid cancer by Shah, Manisha H., Sherman, Eric Jeffrey, Robinson, Bruce, Solomon, Benjamin J., Kang, Hyunseok, Lorch, Jochen H., Worden, Francis P., Brose, Marcia S., Leboulleux, Sophie, Godbert, Yann, Meurer, Marie, Morris, John C., Owonikoko, Taofeek Kunle, Tan, Daniel Shao-Weng, Gautschi, Oliver, Patel, Jyoti D., Yang, Luxi, Kherani, Jennifer, Cabanillas, Maria E., Wirth, Lori J.

“…Abstract only 3594 Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the…”
Get full text

Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC) by Owonikoko, Taofeek Kunle, Borghaei, Hossein, Champiat, Stéphane, Paz-Ares, Luis G., Govindan, Ramaswamy, Boyer, Michael J., Johnson, Melissa Lynne, Udagawa, Hibiki, Hummel, Horst-Dieter, Salgia, Ravi, Blackhall, Fiona Helen, Boosman, Rene J., Lai, Wei-Chu Victoria, Dowlati, Afshin, Vokes, Everett E., Hann, Christine L., Chiang, Anne C., Endraca, Marichu, Soman, Neelesh, Smit, Marie-Anne Damiette

“…Abstract only TPS9080 Background: SCLC is an aggressive neuroendocrine tumor with poor prognosis and few treatment options. Delta-like ligand 3 (DLL3) is an…”
Get full text

Pattern of liver-directed therapies and outcomes in cancer patients hospitalized in the United States by Alese, Olatunji Boladale, Kim, Sungjin, Chen, Zhengjia, Owonikoko, Taofeek Kunle, El-Rayes, Bassel F.

“…Abstract only…”
Get full text

Collection and utilization of oncology big data by Pant, Shubham, Owonikoko, Taofeek Kunle, Magid Diefenbach, Catherine S., Kim, Sungjin, Chen, Zhengjia, Towle, Elaine L., Pierce, Lori J., Mileham, Kathryn Finch

“…Abstract only e18134 Background: Big Data includes data sets whose size is beyond the ability of typical database software tools to capture, store, manage, and…”
Get full text

Small cell carcinoma of the head and neck: Incidence and survival trends based on the Surveillance and Epidemiologic and End Results (SEER) analysis by Bean, Marta, Goodman, Michael, Steuer, Conor Ernst, Patel, Mihir, McDonald, Mark William, Higgins, Kristin Ann, Owonikoko, Taofeek Kunle, Beitler, Jonathan Jay, Shin, Dong Moon, Saba, Nabil F.

“…Abstract only e17508 Background: Small cell carcinomas of the head and neck (SmCCHN) are rare neoplasms with an unfavorable prognosis. Population based data…”
Get full text

Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study by Owonikoko, Taofeek Kunle, Redman, Mary Weber, Byers, Lauren Averett, Griffin, Katie, Hirsch, Fred R., Mack, Philip C., Gandara, David R., Bradley, Jeffrey D., Stinchcombe, Tom, Kelly, Karen, Ramalingam, Suresh S., Herbst, Roy S., Papadimitrakopoulou, Vassiliki

“…Abstract only…”
Get full text